Table: Aska Pharmaceutical Holdings -Q1 group results

ASKA Pharmaceutical Holdings

07/08/2023 07:00

Aug 7 (Reuters)- 
             Aska Pharmaceutical Holdings Co., Ltd. 
             CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)                
                 3 months ended      3 months ended       Year to 
                Jun 30, 2023        Jun 30, 2022     Mar 31, 2024 
                   LATEST             YEAR-AGO          LATEST    
                   RESULTS             RESULTS         FORECAST   
  Sales             16.02               15.27            62.00    
                 (+4.9 pct)          (+7.4 pct)       (+2.5 pct)  
  Operating          1.70                1.66             5.40    
                 (+2.4 pct)          (+40.1 pct)      (+5.7 pct)  
  Recurring          1.81                1.81             5.50    
                 (+0.2 pct)          (+35.8 pct)      (+5.1 pct)  
  Net                1.43                1.32             4.40    
                 (+8.0 pct)          (+20.4 pct)      (+3.8 pct)  
  EPS             50.51 yen           46.94 yen       155.81 yen  
  Ann Div                             16.00 yen        20.00 yen  
  -Q2 div                             8.00 yen         10.00 yen  
  -Q4 div                             8.00 yen         10.00 yen  
  
  NOTE - Aska Pharmaceutical Holdings Co., Ltd.. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4886.T